Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells 2,914 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 2,914 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $7.43, for a total transaction of $21,651.02. Following the completion of the transaction, the chief technology officer owned 1,923,855 shares in the company, valued at approximately $14,294,242.65. The trade was a 0.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

David Badawi also recently made the following trade(s):

• On Tuesday, January 6th, David Badawi sold 3,695 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total transaction of $27,638.60.
• On Monday, January 5th, David Badawi sold 3,051 shares of Sight Sciences stock. The stock was sold at an average price of $7.82, for a total transaction of $23,858.82.

Sight Sciences Stock Down 3.1%

Shares of NASDAQ:SGHT traded down $0.24 during trading on Tuesday, reaching $7.47. 197,717 shares of the stock traded hands, compared to its average volume of 290,394. The stock has a market cap of $394.94 million, a P/E ratio of -8.30 and a beta of 2.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60. The stock has a 50-day moving average of $7.52 and a two-hundred day moving average of $5.13. Sight Sciences, Inc. has a 52-week low of $2.03 and a 52-week high of $9.24.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. The business had revenue of $12.54 million during the quarter. As a group, sell-side analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Raymond James Financial set a $9.00 target price on Sight Sciences in a research report on Monday. Citigroup lifted their price target on shares of Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Morgan Stanley increased their price objective on shares of Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of Sight Sciences from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Finally, UBS Group boosted their target price on shares of Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.30.

Key Stores Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade
• Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing
• Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (<1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. CEO sale filing CTO sale filing Other insider filings

Hedge Funds Weigh In On Sight Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC bought a new stake in Sight Sciences during the first quarter valued at approximately $128,000. Acadian Asset Management LLC boosted its stake in shares of Sight Sciences by 127.7% during the 1st quarter. Acadian Asset Management LLC now owns 432,541 shares of the company’s stock worth $1,033,000 after acquiring an additional 242,559 shares during the last quarter. Strs Ohio bought a new stake in shares of Sight Sciences during the 1st quarter valued at $158,000. Rhumbline Advisers increased its stake in shares of Sight Sciences by 9.5% in the 1st quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock worth $120,000 after purchasing an additional 4,319 shares in the last quarter. Finally, KCK LTD. bought a new position in Sight Sciences in the 2nd quarter worth $18,069,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.